查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602234

白斑症治療藥物市場：依治療方法、疾病類型、藥物類型、最終用戶、通路 - 全球預測 2025-2030

Vitiligo Therapeutics Market by Treatment (Light Therapy, Surgical Procedures, Topical Treatment), Disease Type (Nonsegmental Vitiligo, Segmental Vitiligo), Drug Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年白斑症治療藥物市值為14.5億美元，預計2024年將達到15.6億美元，複合年成長率為8.43%，到2030年預計將達到25.5億美元。

白斑症治療包括旨在控制和逆轉白斑症（一種以色素沉著為特徵的皮膚病）的各種治療和干涉措施。此市場範圍涵蓋各種藥物療法，如局部固醇、Calcineurin抑制劑、照光治療、新型生物製藥和小分子化合物。這些治療的需求源自於醫療和社會心理需求，因為白斑症會導致嚴重的心理困擾和社會恥辱。適用範圍包括醫院、皮膚科診所和家庭治療，最終使用者包括兒童和成人患者。市場促進因素包括尋常型白斑症盛行率的增加、意識的提高以及新療法研發的快速增加。 JAK 抑制劑和基因治療等創新技術的出現為白斑症治療的個人化醫療提供了新領域的潛在機會。透過利用策略聯盟和投資於專注於新治療方法的長期療效和安全性的高級研究，鼓勵利用這些機會進行研究。然而，仍存在可能阻礙市場成長的限制，例如治療成本高、對白斑症病理學的不完全了解以及監管障礙。挑戰包括患者反應的變化和病情的慢性性質，需要繼續研究適應性治療通訊協定。創新領域包括開發非侵入性診斷工具、透過數位健康平台提高患者依從性以及探索微生物組在皮膚健康中的作用。白斑症治療市場的特點是技術快速進步並向以患者為中心的護理模式轉變，呈現出巨大的業務成長潛力。該領域的相關人員應專注於加強學術界、產業和患者倡導團體之間的合作，以促進全面、漸進的治療發展方法。

主要市場統計
基準年[2023] 14.5億美元
預測年份 [2024] 15.6億美元
預測年份 [2030] 25.5億美元
複合年成長率（%） 8.43%

市場動態：揭示快速發展的白斑症治療市場的關鍵市場洞察

白斑症藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球白斑症病例不斷增加
    • 對有效治療方法的認知不斷增強
  • 市場限制因素
    • 白斑症治療和產品召回的潛在風險
  • 市場機會
    • 增加有效白斑藥物開發的臨床試驗及研發活動
    • 白斑症治療藥物的有利報銷方案
  • 市場挑戰
    • 發展中地區的治療方法有限，而且白斑藥物有副作用的風險。

波特五力：駕馭白斑藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解白斑症治療藥物市場的外在影響

外部宏觀環境因素在塑造白斑症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解白斑症治療藥物市場的競爭狀況

白斑症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣白斑症治療藥物市場供應商績效評估

FPNV定位矩陣是評估白斑症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球白斑症病例不斷增加
      • 提高人們對有效治療方法的認知
    • 抑制因素
      • 白斑症治療和產品召回的潛在風險
    • 機會
      • 增加臨床試驗和研發活動，有效開發白斑治療藥物
      • 白斑症治療藥物的有利報銷方案
    • 任務
      • 發展中地區的治療方法有限，且有與白斑藥物相關的副作用風險。
  • 市場區隔分析
    • 治療：光療的重大技術進步
    • 疾病類型：節段性白斑症盛行率上升
    • 藥物類型：JAK抑制劑治療白斑效果良好
    • 最終使用者：由於成本效益，對皮膚科診所的興趣正在增加
    • 分銷通路：網路藥局通路呈現成長趨勢
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依治療分類的白斑症治療藥物市場

  • 光療
  • 外科手術
    • 細胞移植
    • 植皮
  • 局部治療

第7章白斑症治療藥物市場：依疾病類型

  • 非節段性白斑
  • 節段性白斑

第8章白斑症治療藥物市場依藥物類型分類

  • Calcineurin抑制劑
  • Calcipotriene
  • 皮質類固醇
  • JAK抑制劑

第9章白斑症治療藥物市場：依最終用戶分類

  • 醫院
  • 皮膚科診所

第10章白斑症治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 北美、南美白斑症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區白斑症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲白斑症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Clinuvel 開始白斑症國際 III 期研究
    • 艾伯維 (AbbVie) 宣布Upadacitinib(Rinvoc) 在白斑症 2 期臨床試驗中達到主要終點，並將計畫推進至 3 期
    • Glenmark Pharmaceuticals 0.03%Tacrolimus軟膏獲得 sANDA核准
    • AVITA Medical 宣布 FDA核准RECELL 用於白斑症患者的皮膚色素沉著治療
    • Insight 宣布歐盟委員會核准Opzella (Ruxolitinib) 霜用於治療成人和青少年面部非節段性白斑
    • 麻省理工學院陳學院 (MIT Chan College) 向 Ardena Therapeutics 授予 siRNA 化學許可，用於開發皮膚病治療方法
    • 加拿大衛生署核准Edesa Biotech 的白斑症治療試驗
    • Ahamne Biosciences 完成白斑症治療第一期臨床試驗
    • Insight 宣布與 Medixie 支持的 Viralis Therapeutics 就抗 IL-15RB 單株抗體 Auremolimab (VM6) 達成收購協議
    • Almirall 和 Inselm Transfer 簽署白斑症調查合約

公司名單

  • Clinuvel Pharmaceuticals Ltd.
  • Merck KGaA
  • ISSAR pharmaceuticals Pvt. Ltd.
  • Vyne Therapeutics, Inc.
  • Glenmark Pharmaceuticals Limited
  • Organic Care Australia Pty Ltd.
  • AbbVie Inc.
  • TeVido BioDevices
  • SESDERMA, SL
  • Biocon Limited
  • Dermavant Sciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Array Skin Therapy
  • Koninklijke Philips NV
  • Astellas Pharma, Inc.
  • Kernel Medical Equipment Co.,LTD
  • Mylan NV by Viatris Inc.
  • Stem Cell Care India
  • SOMA Skin & Laser, LLC
  • Accord Healthcare, Inc.
  • Incyte Corporation
  • Strides Pharma Science Limited
  • Pierre Fabre SA
  • Panacea Biotec Limited
  • The Daavlin Company
  • Novartis AG
  • Arcutis Biotherapeutics, Inc.
  • Amgen Inc.
  • JN Biosciences LLC
  • Philadelphia Pharmaceuticals
  • Clarify Health Solutions, Inc.
  • Edesa Biotech, Inc.
  • AVITA Medical, Inc.
  • UNIZA Group
  • Temprian Therapeutics Inc.
  • Ahammune Biosciences Pvt. Ltd.
  • Puneet Laboratories Pvt. Ltd.
  • Bausch Health Companies Inc.
  • Pfizer Inc.
  • Nova Dermatology
Product Code: MRR-742BD51851D2

The Vitiligo Therapeutics Market was valued at USD 1.45 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 8.43%, to USD 2.55 billion by 2030.

Vitiligo therapeutics encompass a range of medical treatments and interventions aimed at managing and potentially reversing the effects of vitiligo, a skin condition characterized by the loss of pigmentation. The scope of this market extends across various pharmacological therapies, such as topical corticosteroids, calcineurin inhibitors, phototherapy, and emerging biologics and small molecules. The necessity for these treatments stems from both medical and psychosocial needs, as vitiligo can lead to significant emotional distress and social stigmatization. The application spectrum covers hospital settings, dermatology clinics, and home-based treatments, with end-users including both pediatric and adult patients. Key market drivers include increasing prevalence of vitiligo, heightened awareness, and burgeoning research and development in novel therapeutics. Innovations such as JAK inhibitors and gene therapy emerge as potential opportunities, providing new frontiers for personalized medicine in vitiligo care. Recommendations for leveraging these opportunities involve tapping into strategic alliances and investing in advanced research focused on long-term efficacy and safety profiles of emerging therapies. Nevertheless, limitations persist, including high treatment costs, incomplete understanding of vitiligo's pathogenesis, and regulatory hurdles, which may impede market growth. Challenging factors also involve variability in patient response and the chronic nature of the condition, calling for ongoing research in adaptive treatment protocols. Areas ripe for innovation include developing non-invasive diagnostic tools, enhancing patient adherence through digital health platforms, and exploring the microbiome's role in skin health. The vitiligo therapeutics market is characterized by fast-evolving technological advances and a shift toward patient-centered care models, underscoring the potential for significant business growth. Stakeholders in this sector should focus on increasing collaboration between academia, industry, and patient advocacy groups to foster an inclusive and progressive approach to treatment development.

KEY MARKET STATISTICS
Base Year [2023] USD 1.45 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 2.55 billion
CAGR (%) 8.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vitiligo Therapeutics Market

The Vitiligo Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases of vitiligo across the globe
    • Growing awareness regarding the availability of effective treatments
  • Market Restraints
    • Potential risk of vitiligo drug and product recall
  • Market Opportunities
    • Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
    • Favorable reimbursement scenario for vitiligo therapeutics
  • Market Challenges
    • Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Vitiligo Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vitiligo Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vitiligo Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vitiligo Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vitiligo Therapeutics Market

A detailed market share analysis in the Vitiligo Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vitiligo Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vitiligo Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Vitiligo Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Clinuvel Pharmaceuticals Ltd., Merck KGaA, ISSAR pharmaceuticals Pvt. Ltd., Vyne Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Organic Care Australia Pty Ltd., AbbVie Inc., TeVido BioDevices, SESDERMA, S.L, Biocon Limited, Dermavant Sciences, Inc., Dr. Reddy's Laboratories Ltd., Array Skin Therapy, Koninklijke Philips N.V., Astellas Pharma, Inc., Kernel Medical Equipment Co.,LTD, Mylan N.V. by Viatris Inc., Stem Cell Care India, SOMA Skin & Laser, LLC, Accord Healthcare, Inc., Incyte Corporation, Strides Pharma Science Limited, Pierre Fabre S.A, Panacea Biotec Limited, The Daavlin Company, Novartis AG, Arcutis Biotherapeutics, Inc., Amgen Inc., JN Biosciences LLC, Philadelphia Pharmaceuticals, Clarify Health Solutions, Inc., Edesa Biotech, Inc., AVITA Medical, Inc., UNIZA Group, Temprian Therapeutics Inc., Ahammune Biosciences Pvt. Ltd., Puneet Laboratories Pvt. Ltd., Bausch Health Companies Inc., Pfizer Inc., and Nova Dermatology.

Market Segmentation & Coverage

This research report categorizes the Vitiligo Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Light Therapy, Surgical Procedures, and Topical Treatment. The Surgical Procedures is further studied across Cell Transplant and Skin Graft.
  • Based on Disease Type, market is studied across Nonsegmental Vitiligo and Segmental Vitiligo.
  • Based on Drug Type, market is studied across Calcineurin Inhibitors, Calcipotriene, Corticosteroids, and JAK inhibitor.
  • Based on End User, market is studied across Hospitals and Skin Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of vitiligo across the globe
      • 5.1.1.2. Growing awareness regarding the availability of effective treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of vitiligo drug and product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
      • 5.1.3.2. Favorable reimbursement scenario for vitiligo therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Significant technological advancements in light therapies
    • 5.2.2. Disease Type: Rising prevalence of segmental vitiligo disorder
    • 5.2.3. Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management
    • 5.2.4. End User: Growing preference for skin clinics due to cost effectiveness
    • 5.2.5. Distribution Channel: Rising inclination towards online pharmacy channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vitiligo Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Light Therapy
  • 6.3. Surgical Procedures
    • 6.3.1. Cell Transplant
    • 6.3.2. Skin Graft
  • 6.4. Topical Treatment

7. Vitiligo Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Nonsegmental Vitiligo
  • 7.3. Segmental Vitiligo

8. Vitiligo Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Calcineurin Inhibitors
  • 8.3. Calcipotriene
  • 8.4. Corticosteroids
  • 8.5. JAK inhibitor

9. Vitiligo Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Skin Clinics

10. Vitiligo Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Vitiligo Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vitiligo Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vitiligo Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinuvel Starts Global Phase III Vitiligo Study
    • 14.3.2. AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
    • 14.3.3. Glenmark Pharmaceuticals Receives sANDA Approval for Tacrolimus Ointment, 0.03%
    • 14.3.4. AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
    • 14.3.5. Incyte Announces European Commission Approval Of Opzelura (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
    • 14.3.6. UMass Chan Licensed siRNA chemistry to Aldena Therapeutics To Develop Therapies For Dermatological Diseases
    • 14.3.7. Health Canada Grants Approval for Edesa Biotech's Vitiligo Therapy Trial
    • 14.3.8. Ahammune Biosciences Completes Phase I Clinical Trial For Vitiligo Drug
    • 14.3.9. Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15RB Monoclonal Antibody
    • 14.3.10. Almirall, Inserm Transfert Enter Agreement for Vitiligo Research

Companies Mentioned

  • 1. Clinuvel Pharmaceuticals Ltd.
  • 2. Merck KGaA
  • 3. ISSAR pharmaceuticals Pvt. Ltd.
  • 4. Vyne Therapeutics, Inc.
  • 5. Glenmark Pharmaceuticals Limited
  • 6. Organic Care Australia Pty Ltd.
  • 7. AbbVie Inc.
  • 8. TeVido BioDevices
  • 9. SESDERMA, S.L
  • 10. Biocon Limited
  • 11. Dermavant Sciences, Inc.
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Array Skin Therapy
  • 14. Koninklijke Philips N.V.
  • 15. Astellas Pharma, Inc.
  • 16. Kernel Medical Equipment Co.,LTD
  • 17. Mylan N.V. by Viatris Inc.
  • 18. Stem Cell Care India
  • 19. SOMA Skin & Laser, LLC
  • 20. Accord Healthcare, Inc.
  • 21. Incyte Corporation
  • 22. Strides Pharma Science Limited
  • 23. Pierre Fabre S.A
  • 24. Panacea Biotec Limited
  • 25. The Daavlin Company
  • 26. Novartis AG
  • 27. Arcutis Biotherapeutics, Inc.
  • 28. Amgen Inc.
  • 29. JN Biosciences LLC
  • 30. Philadelphia Pharmaceuticals
  • 31. Clarify Health Solutions, Inc.
  • 32. Edesa Biotech, Inc.
  • 33. AVITA Medical, Inc.
  • 34. UNIZA Group
  • 35. Temprian Therapeutics Inc.
  • 36. Ahammune Biosciences Pvt. Ltd.
  • 37. Puneet Laboratories Pvt. Ltd.
  • 38. Bausch Health Companies Inc.
  • 39. Pfizer Inc.
  • 40. Nova Dermatology

LIST OF FIGURES

  • FIGURE 1. VITILIGO THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VITILIGO THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITILIGO THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VITILIGO THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023